Product
BMS-986036
2 clinical trials
5 indications
Indication
CirrhosisIndication
Fibrosis of the LiverIndication
Nonalcoholic Fatty Liver DiseaseIndication
Non-alcoholic SteatohepatitisIndication
Nonalcoholic SteatohepatitisClinical trial
A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults With Nonalcoholic Steatohepatitis (NASH) and Compensated Liver CirrhosisStatus: Completed, Estimated PCD: 2020-10-08
Clinical trial
Companion Protocol for the ¹³C-Methacetin Breath Test (MBT) for Use in Bristol-Myers Squibb Phase 2b Studies for BMS-986036 (PEG-FGF21), Under Studies Referenced in NCT03486899, NCT03486912Status: Completed, Estimated PCD: 2020-08-18